Mutants of Apolipoproteins A and C

  • C. R. Sirtori
  • M. R. Lovati
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 92)


The determination of the circulating levels of apolipoproteins has become common practice in clinical laboratories, in view of the apparent correlation between levels of specific apolipoproteins and increased or decreased cardiovascular risk [1, 2]. In particular, increased apolipoprotein B levels, both in whole plasma and in specific lipoprotein fractions, e.g. low density lipoproteins (LDL) [3], seem to be associated to a raised risk, the opposite being the case for apo AI [4]. Increased apolipoprotein (apo) E levels have been described in primary dysbetalipoproteinemia, often associated with premature vascular diseases [5]; on the other hand, the reductions of both apo AI and, as more recently described, apo D levels [6], seem to be correlated with a raised cardiovascular risk. Similar correlations for other apolipoproteins, although evaluated by numerous Authors, have not provided univocal findings in terms of predictivity of risk.

Key Words

Lipoproteins Mutants Atherosclerosis Lecithin Cholesterol Acyltrans-ferase Lipoprotein Lipase Molecular Biology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Avogaro P, Bittolo-Bon G, Cazzolato G, Quinci GB (1979) Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet i: 901–903CrossRefGoogle Scholar
  2. 2.
    Noma A Yokosuka T, Kitamura K (1983) Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease. Atherosclerosis 49:1–7-3.PubMedCrossRefGoogle Scholar
  3. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO (1982) Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 97:833–839PubMedCrossRefGoogle Scholar
  4. 4.
    Kukita M, Hiwada K, Kokubu T (1984) Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis 51:261–267PubMedCrossRefGoogle Scholar
  5. 5.
    Havel RJ, Kane P. (1973) Primary dysbetalipoproteinemia, predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc Natl Acad Sci USA 70:2015–2018PubMedCrossRefGoogle Scholar
  6. 6.
    James RW, Martin B, Pometta D, Grab B, Suenram A (1985) Apoprotein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis 60:49–53CrossRefGoogle Scholar
  7. 7.
    Breslow JL (1984) Molecular genetics of lipoprotein disorders. Circulation 69:1190–1194PubMedCrossRefGoogle Scholar
  8. 8.
    Zannis VI, Breslow JL (1982) Apolipoprotein E. Mol Cell Biochem 42:3–20PubMedCrossRefGoogle Scholar
  9. 9.
    Franceschini G, Sirtori CR, Capurso A, Weisgraber KM, Mahley RW (1980) Al-Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 66:892–900PubMedCrossRefGoogle Scholar
  10. 10.
    Swaney JB, Braithwaite F, Eder HA (1977) Characterization of the apolipoproteins of rat plasma lipoproteins. Biochemistry 16:271–278PubMedCrossRefGoogle Scholar
  11. 11.
    Fidge NH (1980) The redistribution and metabolism of iodinated apolipoprotein AIV in rats. Biochim Biophys Acta 619:129–141PubMedCrossRefGoogle Scholar
  12. 12.
    Swift LL, Soulé PD, Gray ME, Le Quire VS: Intestinal lipoprotein synthesis. Comparison of nascent Golgi lipoproteins from chow-fed and hypercholesterolemic rats. J Lipid Res 25:1–13Google Scholar
  13. 13.
    Weinberg RB, Spector MS (1985) Structural properties and lipid binding of human apolipoprotein AIV. J Biol Chem 260:4914–4921PubMedGoogle Scholar
  14. 14.
    Chen CH, Albers JJ (1985) Activation of lecithin:cholesterol acyltransferase by apolipoproteins E-2, E-3, and AIV isolated from human plasma. Biochim Biophys Acta 836:279–285PubMedCrossRefGoogle Scholar
  15. 15.
    Karathanasis SK (1985) Apolipoprotein multigene family: tandem organisation of human apolipoprotein AI, CIII, and AIV genes Proc Natl Acad Sci USA 82:6374–6378CrossRefGoogle Scholar
  16. 16.
    Brewer HB, Fairwell T, La Rue A, Rorian R, Hauser A, Bronzert TJ (1978) The amino acid sequence of human apo AI, an apolipoprotein isolated from high density lipoproteins. Biochim Biophys Res Comm 80:623–629CrossRefGoogle Scholar
  17. 17.
    Zannis VI, Karathanasis SK, Kentmann HT, Goldberg G, Breslow JL (1983) Intracellular and extracellular processing of human apolipoprotein AI: secreted apolipoprotein AI isoprotein 2 is a propeptide. Proc Natl Acad Sci USA 80:2574–2578PubMedCrossRefGoogle Scholar
  18. 18.
    Oram JF (1983) Effects of high density lipoprotein subfractions on cholesterol homeostasis in human fibroblasts and arterial smooth muscle cells. Arteriosclerosis 3:420–432PubMedCrossRefGoogle Scholar
  19. 19.
    Weisgraber KH, Mahley RW (1978) Apoprotein (E-AII) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem 253:6281–6288PubMedGoogle Scholar
  20. 20.
    Schamaun O, Olaisen B, Gedde-Dahl T jr, Teisberg P (1983) Genetic studies of an apo AI lipoprotein variant. Hum Genet 64:380–383 -PubMedCrossRefGoogle Scholar
  21. 21.
    Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR (1980) AI-Milano apoprotein. Isolation and characterization of a cysteine-containing variant of the AI apoprotein from human high density lipoproteins. J Clin Invest 66:901–907PubMedCrossRefGoogle Scholar
  22. 22.
    Weisgraber KH, Rall SC Jr, Bersot TP, Mahley RW, Fraceschini G, Sirtori CR (1983) Apolipoprotein AI-Milano: Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J Biol Chem 258:2508–2513PubMedGoogle Scholar
  23. 23.
    Gualandri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB, Cerrone A, Menotti A, (1985) AI Milano apoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 37:1083–1097PubMedGoogle Scholar
  24. 24.
    Franceschini G, Frosi TG, Manzoni C, Gianfraceschi G, Sirtori CR (1982) High density lipoproteins heterogeneity in subjects with the apo AI-Milano variant. J Biol Chem 257:9926–9930 -PubMedGoogle Scholar
  25. 25.
    Franceschini G, Vecchio G, Gianfraceschi G, Magani G, Sirtori CR, (1985) Apolipoprotein AI Milano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem 260:16321–16325PubMedGoogle Scholar
  26. 26.
    Rall SC Jr, Weisgraber KH, Mahley RW, Ogawa Y, Fielding CJ, Utermann G, Haas J, Steinmetz A, Menzel HJ, Assmann G (1984) Abnormal lecithin: cholesterol acyltransferase activation by a human apolipoprotein AI variant in which a single lysine residue is deleted. J Biol Chem 259:10063–10070PubMedGoogle Scholar
  27. 27.
    Utermann G, Haas J, Steinmetz A, Paetzold SC, Rall SC jr, Weisgraber KH, Mahley RW (1984) Apolipoprotein AL-Gießen: apo A-I (Pro143 → Arg). A mutant that is defective in activating lecithin: cholesterol acyltransferase. Eur J Biochem 144:325–331Google Scholar
  28. 28.
    Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P (1982) Familial deficiency of apolipoproteins AI and C III and precocious coronary-artery disease. N Engl J Med 306:1513–1519PubMedCrossRefGoogle Scholar
  29. 29.
    Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB jr (1982) Plasma apolipoprotein AI absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2:16–26PubMedCrossRefGoogle Scholar
  30. 30.
    Karathanasis SK, Norum RA, Zannis VI, Breslow JL (1983) An inherited polymorphism in the human apolipoprotein AI gene locus related to the development of atherosclerosis. Nature 301:718–720PubMedCrossRefGoogle Scholar
  31. 31.
    Schaefer EJ, Ordovas JM, Law SW, Ghiselli GC, Kashyap MT, Srivastava LS, Heaton WH, Albers JJ, Connor WE, Lindgren FT, Lemeshev Y, Segrest JP, Brewer HB jr (1985) Familial apolipoprotein AI and CIII deficiency, variant II. J Lipid Res 26:1089–1101PubMedGoogle Scholar
  32. 32.
    Fredrickson DS (1965) The inheritance of high density lipoprotein deficiency (Tangier disease). J Clin Invest 44:228–237Google Scholar
  33. 33.
    Carlson LA (1982) Fish eye disease: a new familial condition with massive corneal opacities and dyslipoproteinemia. Eur J Clin Invest 12:41–53PubMedCrossRefGoogle Scholar
  34. 34.
    Schaefer EJ, Kay LL, Zech LA, Brewer HB jr (1982) Tangier disease: high density lipoprotein deficiency due to defective metabolism of an abnormal apolipoprotein A-I (Apo A-ITangier). J Clin Invest 70:934–945PubMedCrossRefGoogle Scholar
  35. 35.
    Rees A, Stocks J, Shoulders C, Carlson LA, Baralle FE, Galton DJ (1984) Restriction enzyme analysis of the apolipoprotein AI gene in Fish Eye Disease and Tangier Disease. Acta Med Scand 215:235–237PubMedCrossRefGoogle Scholar
  36. 36.
    Law SW, Brewer HB jr (1985) Tangier Disease: The complete mRNA sequence encoding for preproapo-A-I. J Biol Chem 260:12810–12814PubMedGoogle Scholar
  37. 37.
    Schmitz G, Assmann G, Robenek H, Brennhausen B (1985) Tangier disease: a disorder of intracellular membrane traffic. Proc Natl Acad Sci USA 82:6305–6309PubMedCrossRefGoogle Scholar
  38. 38.
    Carlson LA, Holmquist L (1985) Evidence for deficiency of high density lipoprotein lecithin: cholesterol acyltransferase activity (α-LCAT) in Fish Eye disease. Acta Med Scand 218:189–196PubMedCrossRefGoogle Scholar
  39. 39.
    Kinnunen PKJ, Jackson RL, Smith LC, Gotto AM jr, Sparrow JT (1977) Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein CIL Proc Natl Acad Sci USA 74:4848–4851CrossRefGoogle Scholar
  40. 40.
    Lukens TW, Borensztajn J (1978) Effects of C apoproteins on the activity of endothelium-bound lipoprotein lipase. Biochem J 175:1143–1146PubMedGoogle Scholar
  41. 41.
    Windier E, Chao YS, Havel RJ (1980) Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem 255:5475–5480Google Scholar
  42. 42.
    Shelburne FJ, Meyers HW, Quarfordt S (1980) Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest 65:652–658PubMedCrossRefGoogle Scholar
  43. 43.
    Soutar AK, Sigler GF, Smith LC, Gotto AM jr, Sparrow JT (1978) Lecithin: cholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein CI. Scand J Clin Lab Invest 38 (Suppl 150): 53–38CrossRefGoogle Scholar
  44. 44.
    Humphries SE, Berg K, Gill L, Cumming AM, Robertson FW, Stalenhoef AFH, Williamson R, Borresen AL (1984) The gene for apolipoprotein C-II is closely linked to the gene for apolipoprotein E on chromosome 19. Clin Genet 26:389–396 -PubMedCrossRefGoogle Scholar
  45. 45.
    Myklebost O, Rogne S, Loasen B, Gedde-Dahl T jr, Prydz H (1984) The locus for apolipoprotein C-II is closely linked to the apolipoprotein E locus on chromosome 19 in man. Hum Genet 67:309–312PubMedCrossRefGoogle Scholar
  46. 46.
    Breckenridge WC, Little JA, Steiner G, Chow A, Poast M (1978) Hypertriglyceridemia associated with deficiency of apolipoprotein CII. N Engl J Med 298:1265–1273PubMedCrossRefGoogle Scholar
  47. 47.
    Breckenridge WC, Cox D, Little JA (1978) Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med 299:1421–1424PubMedCrossRefGoogle Scholar
  48. 48.
    Yamamura T, Sudo H, Ishikawa K, Yamamoto A (1979) Familial type I hyperlipoproteinemia caused by apolipoprotein CII deficiency. Atherosclerosis 34:53–65PubMedCrossRefGoogle Scholar
  49. 49.
    Miller NE, Rao SN, Alaupovic L, Noble N, Slack Y, Brunzell Y D, Lewis B (1981) Familial apolipoprotein CII deficiency: plasma lipoproteins and apolipoproteins in heterozygous and homozygous subjects and the effects of plasma infusion. Eur J Clin Invest 11:69–76PubMedCrossRefGoogle Scholar
  50. 50.
    Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Baldo Enzi G, Verlato F, Baiocchi MR, Sprecher DL, Kashyap ML, Brewer HB jr, Crepaldi G (1986) Apolipoprotein CII deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients J Clin Invest 77:520–527Google Scholar
  51. 51.
    Cox DW, Breckenridge WC, Little JA (1978) Inheritance of apolipoprotein CII deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med 299:1421–1424PubMedCrossRefGoogle Scholar
  52. 52.
    Maguire GH, Little JA, Kakis G, Breckenridge WC (1984) Apolipoprotein C-II deficiency associated with nonfunctional mutant forms of apolipoprotein C-II. Can J Biochem 62:847–852CrossRefGoogle Scholar
  53. 53.
    Crepaldi G, Fellin R, Baggio G, Augustin J, Greten H (1980) Lipoprotein and apoprotein, adipose tissue and hepatic lipoprotein lipase levels in patients with hyperchylomicronemia and their immediate family members. In: Gotto AM jr, Smith LC, Allen B (eds) Atherosclerosis V. Springer, New York, pp 250–254CrossRefGoogle Scholar
  54. 54.
    Sprecher DL, Taam L, Brewer HB jr (1984) Two dimensional electrophoresis of human plasma apolipoproteins. Clin Chem 30:2084–2092PubMedGoogle Scholar
  55. 55.
    Menzel HJ, Kane JP, Malloy HJ, Havel RJ (1986) A variant primary structure of apolipoprotein CII in individuals of African descent J Clin Invest 77:595–601PubMedCrossRefGoogle Scholar
  56. 56.
    Havel RJ, Kotite L, Kane JP (1979) Isoelectric heterogeneity of the cofactor protein for lipoprotein lipase in human blood plasma. Biochem Med 21:121–128PubMedCrossRefGoogle Scholar
  57. 57.
    Mahley RW, Innerarity TL, Rall SC jr, Weisgraber KH (1984) Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 25:1277–1294PubMedGoogle Scholar

Copyright information

© J. F. Bergmann Verlag, München 1986

Authors and Affiliations

  • C. R. Sirtori
    • 1
  • M. R. Lovati
    • 1
  1. 1.Institute of Pharmacological Sciences, Chair of Chemotherapy and Center E. Grossi PaolettiUniversity of MilanoMilanoItaly

Personalised recommendations